The Business Research Company’s report on the Leukemia Therapeutics Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How are market drivers shaping the future growth trajectory of the leukemia therapeutics industry?
The rising prevalence of leukemia is driving the growth of the leukemia therapeutics market. Leukemia is a type of blood cancer that starts in the bone marrow and proceeds to uncontrolled blood cell growth. The increased accessibility of medical treatment to leukemia patients across the globe and the growing availability of treatment options have contributed to increased demand for leukemia therapeutics. For instance, in January 2023, according to a report published by the American Cancer Society, a US-based health organization, it is anticipated that there will be around 59,610 new instances of leukemia of all types and approximately 23,710 fatalities in 2023 resulting from leukemia of all types in the United States. Additionally, an estimated 20,380 new cases of acute myeloid leukemia (AML) and about 11,310 AML-related deaths are expected in the same year. Therefore, the rising prevalence of leukemia is contributing to the growth of the leukemia therapeutics market.
Access Your Free Sample of the Global Leukemia Therapeutics Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=6358&type=smp
What is the estimated market size of the leukemia therapeutics sector by 2029, based on current forecasts?
The leukemia therapeutics market size has grown strongly in recent years. It will grow from $17.57 billion in 2024 to $18.85 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to growth in geriatric population, improved diagnostics leading to early detection of leukemia, increasing prevalence of leukemia, growing investment in research and development, expansion of personalized medicine approaches.
The leukemia therapeutics market size is expected to see strong growth in the next few years. It will grow to $25.91 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to development of novel immunotherapies for leukemia, growing focus on precision medicine in leukemia treatment, expansion of indications for existing leukemia therapies, increased adoption of gene therapies, advances in supportive care for leukemia patients. Major trends in the forecast period include integration of biomarker-driven approaches, rise of combination therapies for enhanced efficacy, emphasis on minimal residual disease monitoring, increasing use of car-t cell therapies, exploration of targeted therapies based on leukemia subtypes.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=6358&type=smp
#Who are the top players in the leukemia therapeutics market?
Major companies operating in the leukemia therapeutics market include Novartis International AG, AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche AG, Sanofi S. A., Agios Pharmaceuticals, Amgen Inc., Argenx SE, Astellas Pharma Inc., BioLineRx Ltd., Cellerant Therapeutics Inc., Daiichi Sankyo Company Limited, Forma Therapeutics Inc., Gilead Sciences Inc., Incyte Corporation, Jazz Pharmaceuticals plc, Johnson & Johnson, Mirati Therapeutics Inc., Molecular Templates Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Seattle Genetics Inc., Stemline Therapeutics Inc., Sunesis Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, TG Therapeutics Inc., Allogene Therapeutics Inc., Blueprint Medicines Corporation, Karyopharm Therapeutics Inc., Verastem Oncology Inc.
#What are the major trends in the leukemia therapeutics market?
Major companies operating in the leukemia therapeutics market are adopting a strategic partnership approach to help the business launch and commercialize its first advanced cancer treatment in the United States. Strategic partnerships refer to a process in which companies leverage each other’s strengths and resources to achieve mutual benefits and success. For instance, in February 2023, Xspray Pharma AB, a Sweden-based biotechnology company, partnered with EVERSANA, a US-based company that provides commercial IT & Communication Technology to the life sciences industry. The partnership aims to facilitate the U.S. launch and commercialization of the company’s first innovative cancer therapy, Dasynoc, intended for treating chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Xspray Pharma will retain financial and strategic control while granting EVERSANA exclusive rights for commercialization to support the Dasynoc launch, scheduled for the second half of 2023.
Which geography holds the highest leukemia therapeutics market share?
North America was the largest region in the leukemia therapeutics market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukemia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report
How do different segments contribute to the overall expansion of the leukemia therapeutics market?
The leukemia therapeutics market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Immunotherapy, Targeted Therapy, Other Treatments
2) By Type Of Leukemia: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Type Of Leukemia
3) By Molecule Type: Small Molecules, Biologics
4) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Chemotherapy: Alkylating Agents, Antimetabolites, Plant Alkaloids, Corticosteroids
2) By Immunotherapy: Monoclonal Antibodies, CAR T-Cell Therapy, Immune Checkpoint Inhibitors, Vaccines
3) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), BCL-2 Inhibitors, IDH Inhibitors, Other Targeted Agents
4) By Other Treatments: Radiation Therapy, Stem Cell Transplantation, Supportive Care Treatments
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6358
How is the leukemia therapeutics market defined?
Leukemia therapeutics refer to a treatment used to treat an aggressive (quickly spreading) malignancy in which the blood or bone marrow contain an excessive amount of myeloblasts (immature white blood cells). The type treatment for leukemia depends on various factors such as age, overall health, type of leukemia, its current condition within the body and others.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
